1. Cloxacillin: potential risk of acute kidney injury

   News item 01 April 2023 Pages: 1 - 1

2. Developmental disabilities after in utero exposure to topiramate

   News item 01 April 2023 Pages: 2 - 2

3. Diazoxide-related pericardial effusion

   News item 01 April 2023 Pages: 3 - 3

4. GLP-1 receptor agonists and tirzepatide gall bladder-related AEs

   News item 01 April 2023 Pages: 4 - 4

5. Liraglutide and semaglutide may cause serious AEs

   News item 01 April 2023 Pages: 5 - 5

6. Measures for reducing risks of respiratory failure and sepsis with terlipressin

   News item 01 April 2023 Pages: 6 - 6

7. Piperacillin/tazobactam-related haemophagocytic lymphohistiocytosis

   News item 01 April 2023 Pages: 7 - 7

8. Baseline factors associated with pemetrexed-related acute toxicity

   Clinical study 01 April 2023 Pages: 8 - 8

9. Emicizumab: positive AE signals for arthralgia and injection-site pain, but also for some serious AEs

   Clinical study 01 April 2023 Pages: 9 - 9

10. Montelukast increases risk of neuropsychiatric events

    Clinical study 01 April 2023 Pages: 10 - 10

11. Subgroups at high and low risk of tofacitinib-related cancer and MACE

    Clinical study 01 April 2023 Pages: 11 - 11

12. Talimogene laherparepvec increases risk of skin disorders in patients receiving ICIs

    Clinical study 01 April 2023 Pages: 12 - 12

13. Other adverse reaction research

    News item 01 April 2023 Pages: 13 - 13

14. 17dd-yellow-fever-vaccine

    Case report 01 April 2023 Pages: 14 - 14

15. Acenocoumarol/enoxaparin-sodium

    Case report 01 April 2023 Pages: 15 - 15

16. Acetazolamide

    Case report 01 April 2023 Pages: 16 - 16

17. Aciclovir

    Case report 01 April 2023 Pages: 17 - 17

18. Ad26.COV2-S

    Case report 01 April 2023 Pages: 18 - 18

19. Ad26.cov2-s

    Case report 01 April 2023 Pages: 19 - 19

20. Ad26.COV2-S

    Case report 01 April 2023 Pages: 20 - 20

21. Aflibercept/bevacizumab/ranibizumab

    Case report 01 April 2023 Pages: 21 - 21

22. Aflibercept/brolucizumab

    Case report 01 April 2023 Pages: 22 - 22

23. Alectinib/ensartinib

    Case report 01 April 2023 Pages: 23 - 23

24. Alemtuzumab

    Case report 01 April 2023 Pages: 24 - 24

25. Alendronic-acid/ibandronic-acid

    Case report 01 April 2023 Pages: 25 - 25

26. Allopurinol

    Case report 01 April 2023 Pages: 26 - 26

27. Alteplase

    Case report 01 April 2023 Pages: 27 - 27

28. Amikacin

    Case report 01 April 2023 Pages: 28 - 28

29. Amlodipine

    Case report 01 April 2023 Pages: 29 - 29

30. Amphotericin B/voriconazole

    Case report 01 April 2023 Pages: 30 - 30

31. Amphotericin-B-liposomal

    Case report 01 April 2023 Pages: 31 - 31

32. Amphotericin-b-liposomal/colistin/linezolid

    Case report 01 April 2023 Pages: 32 - 32

33. Amphotericin-B-liposomal/flucytosine

    Case report 01 April 2023 Pages: 33 - 33

34. Anakinra/etanercept/methotrexate

    Case report 01 April 2023 Pages: 34 - 34

35. Andexanet-alfa/heparin/plasma

    Case report 01 April 2023 Pages: 35 - 35

36. Antiacnes/Antibacterials/Anti-inflammatories

    Case report 01 April 2023 Pages: 36 - 36

37. Antibacterials/dexamethasone

    Case report 01 April 2023 Pages: 37 - 37

38. Antidepressants/clonazepam

    Case report 01 April 2023 Pages: 38 - 38

39. Antihistamines/elasomeran/prednisone/tozinameran

    Case report 01 April 2023 Pages: 39 - 39

40. Antihypertensives/magnesium-sulfate

    Case report 01 April 2023 Pages: 40 - 40

41. Antihypoglycaemics/tozinameran

    Case report 01 April 2023 Pages: 41 - 41

42. Antineoplastics

    Case report 01 April 2023 Pages: 42 - 42

43. Antineoplastics

    Case report 01 April 2023 Pages: 43 - 43

44. Antineoplastics

    Case report 01 April 2023 Pages: 44 - 44

45. Antineoplastics

    Case report 01 April 2023 Pages: 45 - 45

46. Antineoplastics

    Case report 01 April 2023 Pages: 46 - 46

47. Antineoplastics

    Case report 01 April 2023 Pages: 47 - 47

48. Antineoplastics

    Case report 01 April 2023 Pages: 48 - 48

49. Antineoplastics

    Case report 01 April 2023 Pages: 49 - 49

50. Antineoplastics

    Case report 01 April 2023 Pages: 50 - 50